Actio Biosciences Secures $66 Million in Series B Financing

Clinical-stage biotech company Actio Biosciences closes $66 million Series B financing with new and existing investors.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here